Influence of Guarem on Carbohydrate and Lipid Metabolism, Anthropometric Indices in Patients with Type 2 Diabetes Mellitus

Main Article Content

V.I. Pankiv


The authors carried out open-label study with the use of a standard recommended dose of Guarem. The study included 26 patients with diabetes mellitus type 2 — 15 women and 11 men aged from 29 to 64 years (mean age 57.4 ± 1.8 years). Before the start of the study and during the entire observation, they received the previous glucose-lowering therapy with metformin preparations in a constant dose. Application of Guarem in combination therapy of patients with type 2 diabetes mellitus has a positive impact on the anthropometric indicators, the state of carbohydrate and lipid metabolism. The level of postprandial glycemia on the background of combined therapy with the addition of Guarem significantly decreased by 2.1 mmol/l, HbA1c — by 0.8 %, insulin resistance index HOMA-IR — by 21.2 %. 73.1 % of patients achieved target levels of glycemia. During the study period, the patients who were treated with Guarem tended to reduce total cholesterol (10.5 %; p > 0.05); low-density lipoprotein cholesterol significantly decreased by 0.8 mmol/l (25.8 %); triglyceride level — by 0.9 mmol/l that generally enables to evaluate the results as positive. During the study, most patients (92.3 %) reported good tolerability of the drug. During the observation, hypoglycemia and allergic reactions were not detected, which suggests a good safety profile and tolerability of Guarem. Multifactorial effects of Guarem makes it possible to recommend its inclusion in the combined therapy of patients with type 2 diabetes mellitus associated with overweight, obesity and dyslipidemia.

Article Details

How to Cite
Pankiv, V. “Influence of Guarem on Carbohydrate and Lipid Metabolism, Anthropometric Indices in Patients With Type 2 Diabetes Mellitus”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 3.67, June 2015, pp. 87-91, doi:10.22141/2224-0721.3.67.2015.75278.
Original Researches


Арутюнов Г.П. Терапия факторов риска сердечно-сосудистых заболеваний [руководство] / Арутюнов Г.П. — М.: ГЭОТАР-Медиа, 2010. — 672 с.

Братусь В.В. Ожирение, инсулинорезистентность, метаболический синдром: фундаментальные и клинические аспекты / В.В. Братусь, Т.В. Талева, В.А. Шумаков. — К.: Четверта хвиля, 2009. — 416 с.

Ефимов А.С. Патогенез и лечение хронических осложнений сахарного диабета / А.С. Ефимов, Н.Д. Тронько, Л.К. Соколова // Вісник фармакології та фармації. — 2007. — № 11 — С. 27-34.

Левит Ш. Сахарный диабет 2-го типа: время изменить концепцию / Ш. Левит, Ю.И. Филиппов, А.С. Горелышев // Сахарный диабет. — 2013. — № 1. — С. 91-102.

Маньковский Б.Н. Сердечно-сосудистые заболевания у больных сахарным диабетом: что важно знать кардиологу, эндокринологу и неврологу / Б.Н. Маньковский, О.Н. Барна // Ліки України. — 2010. — № 4 (140). — С. 24-28.

Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence // Diabetes Care. — 2005. — Vol. 28. — P. 1769-1778.

Пасєчко Н.В., Лой Г.Я., Свистун І.І. Вплив препарату Гуарем на масу тіла та основні показники вуглеводного і ліпідного обміну у пацієнтів з надмірною масою тіла чи ожирінням // Міжнародний ендокринологічний журнал. — 2014. — № 5 (61). — С. 31-36.

Type 2 diabetes in practice / Ed. by A.J. Krentz, C.J. Bailey. — Royal Society of Medicine Press Ltd., 2007. — 190 p.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>